235 related articles for article (PubMed ID: 26370156)
1. RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.
Cheng H; Zou Y; Ross JS; Wang K; Liu X; Halmos B; Ali SM; Liu H; Verma A; Montagna C; Chachoua A; Goel S; Schwartz EL; Zhu C; Shan J; Yu Y; Gritsman K; Yelensky R; Lipson D; Otto G; Hawryluk M; Stephens PJ; Miller VA; Piperdi B; Perez-Soler R
Cancer Discov; 2015 Dec; 5(12):1262-70. PubMed ID: 26370156
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
[TBL] [Abstract][Full Text] [Related]
3. P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer.
Venkatesha VA; Joshi A; Venkataraman M; Sonawane V; Bhatia D; Tannu P; Bose J; Choudhari S; Srivastava A; Pandey PK; Lad VJ; Sangana R; Ahmed T; Damre A; Deore V; Sahu B; Kumar S; Sharma S; Agarwal VR
Mol Cancer; 2014 Dec; 13():259. PubMed ID: 25466244
[TBL] [Abstract][Full Text] [Related]
4. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
[TBL] [Abstract][Full Text] [Related]
5. RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR.
Sakre N; Wildey G; Behtaj M; Kresak A; Yang M; Fu P; Dowlati A
Oncotarget; 2017 Jan; 8(4):5992-6002. PubMed ID: 27863413
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
7. mTORC1 is a target of nordihydroguaiaretic acid to prevent breast tumor growth in vitro and in vivo.
Zhang Y; Xu S; Lin J; Yao G; Han Z; Liang B; Zou Z; Chen Z; Song Q; Dai Y; Gao T; Liu A; Bai X
Breast Cancer Res Treat; 2012 Nov; 136(2):379-88. PubMed ID: 23053656
[TBL] [Abstract][Full Text] [Related]
8. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of mTOR complex 2 induces GSK3/FBXW7-dependent degradation of sterol regulatory element-binding protein 1 (SREBP1) and suppresses lipogenesis in cancer cells.
Li S; Oh YT; Yue P; Khuri FR; Sun SY
Oncogene; 2016 Feb; 35(5):642-50. PubMed ID: 25893295
[TBL] [Abstract][Full Text] [Related]
10. mTOR in Lung Neoplasms.
Krencz I; Sebestyen A; Khoor A
Pathol Oncol Res; 2020 Jan; 26(1):35-48. PubMed ID: 32016810
[TBL] [Abstract][Full Text] [Related]
11.
Kim LC; Rhee CH; Chen J
Mol Cancer Res; 2020 Nov; 18(11):1675-1684. PubMed ID: 32801163
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of 14-3-3 binding to Rictor of mTORC2 for Akt phosphorylation at Ser473 is regulated by selenoprotein W.
Jeon YH; Park YH; Kwon JH; Lee JH; Kim IY
Biochim Biophys Acta; 2013 Oct; 1833(10):2135-42. PubMed ID: 23680186
[TBL] [Abstract][Full Text] [Related]
13. New development of inhibitors targeting the PI3K/AKT/mTOR pathway in personalized treatment of non-small-cell lung cancer.
Sun Z; Wang Z; Liu X; Wang D
Anticancer Drugs; 2015 Jan; 26(1):1-14. PubMed ID: 25304988
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and therapeutic implications of mTORC1 and Rictor expression in human breast cancer.
Wazir U; Newbold RF; Jiang WG; Sharma AK; Mokbel K
Oncol Rep; 2013 May; 29(5):1969-74. PubMed ID: 23503572
[TBL] [Abstract][Full Text] [Related]
15. Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma.
Krencz I; Sebestyen A; Papay J; Lou Y; Lutz GF; Majewicz TL; Khoor A
Hum Pathol; 2019 Nov; 93():74-80. PubMed ID: 31454632
[TBL] [Abstract][Full Text] [Related]
16. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
17. Rictor/mammalian target of rapamycin 2 regulates the development of Notch1 induced murine T-cell acute lymphoblastic leukemia via forkhead box O3.
Hua C; Guo H; Bu J; Zhou M; Cheng H; He F; Wang J; Wang X; Zhang Y; Wang Q; Zhou J; Cheng T; Xu M; Yuan W
Exp Hematol; 2014 Dec; 42(12):1031-40.e1-4. PubMed ID: 25201756
[TBL] [Abstract][Full Text] [Related]
18. Resistance to mTORC1 Inhibitors in Cancer Therapy: From Kinase Mutations to Intratumoral Heterogeneity of Kinase Activity.
Faes S; Demartines N; Dormond O
Oxid Med Cell Longev; 2017; 2017():1726078. PubMed ID: 28280521
[TBL] [Abstract][Full Text] [Related]
19. Rictor/mTORC2 protects against cisplatin-induced tubular cell death and acute kidney injury.
Li J; Xu Z; Jiang L; Mao J; Zeng Z; Fang L; He W; Yuan W; Yang J; Dai C
Kidney Int; 2014 Jul; 86(1):86-102. PubMed ID: 24451322
[TBL] [Abstract][Full Text] [Related]
20. Targeting PI3K/AKT/mTOR pathway in non small cell lung cancer.
Fumarola C; Bonelli MA; Petronini PG; Alfieri RR
Biochem Pharmacol; 2014 Aug; 90(3):197-207. PubMed ID: 24863259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
